When is the Spanner® temporary prostatic stent indicated for benign prostatic hyperplasia, and what are the placement criteria, contraindications, and follow‑up recommendations?

The Spanner® Temporary Prostatic Stent for BPH

The Spanner® temporary prostatic stent should be reserved exclusively for catheter-dependent men with confirmed bladder contractility who are either too high-risk for surgery or require temporary relief following transurethral microwave thermotherapy (TUMT), but it is NOT appropriate for routine BPH management or for patients unfit for surgery without proven detrusor function.

Primary Indications

The Spanner stent has three specific clinical scenarios where evidence supports its use:

1. Post-TUMT Obstruction Relief

• Most robust indication: Following TUMT when therapy-induced prostatic edema causes severe obstruction 1
• Placement after routine post-procedure Foley catheterization
• Duration: 4 weeks of use
• Outcomes show significantly greater improvements in post-void residual, uroflowmetry, and IPSS at 1-2 weeks compared to standard catheterization
• Patient satisfaction exceeds 86% 1

2. Catheter-Dependent Men with Bladder Contractility

• Critical requirement: Confirmed detrusor contractility must be documented before placement 2
• Extended use up to 3 cycles of 30 days (90 days total)
• Success rate: 73.8% maintained PVR ≤150 ml throughout trial duration 2
• Mean improvements: Qmax 11.2 ml/s, IPSS decreased to 7.5, QOL score 2.0 2

3. Acute Urinary Retention with Surgical Contraindications

• Only when bladder contractility is preserved
• Not for chronic retention without proven detrusor function
• Requires trial period to assess tolerance 3

Absolute Contraindications

Do NOT use the Spanner stent in:

• Patients "unfit for surgery" without confirmed bladder contractility—63% failure rate with retention or unbearable symptoms requiring removal 3
• Men without demonstrable detrusor function on urodynamic studies
• Routine symptomatic BPH without retention (per AUA guidelines, stents reserved for high-risk patients) 4

Placement Criteria

Pre-Placement Requirements:

1. Urodynamic confirmation of bladder contractility (not explicitly stated but implied by success criteria)
2. Documented catheter dependence (Foley or intermittent catheterization)
3. PVR measurement and baseline uroflowmetry
4. Baseline IPSS and QOL assessment
5. Patient age typically >70 years (mean 77.1 years in trials) 2

Technical Placement:

• Performed under topical anesthesia (local anesthesia sufficient) 5
• Outpatient procedure
• Design includes proximal balloon (prevents distal displacement), reinforced stent spanning prostatic urethra, distal anchor mechanism, and retrieval suture extending to meatus 5
• Radiographic confirmation of position recommended 5

Follow-Up Protocol

During Stent Use:

• Week 1 and 2: Assess PVR, Qmax, IPSS, QOL, adverse events 1
• Week 4: Repeat assessments; consider removal if post-TUMT indication 1
• Week 5 and 8: Post-removal follow-up for sustained improvement 1
• Monthly for extended use: PVR, flow rate, symptom scores at each 30-day cycle 2

Stent Replacement Schedule:

• Post-TUMT: Single 4-week placement, then remove 1
• Extended catheter-dependent use: Replace every 30 days for up to 3 cycles 2
• Trial in surgical non-candidates: 3-month trial maximum, then assess for permanent stenting or alternative management 3

Expected Outcomes and Complications

Efficacy:

• Qmax improvement: 42% increase (8.2 to 11.6 ml/s) 5
• PVR reduction: 64% decrease (312 to 112 ml) 5
• IPSS improvement: 68% decrease (22.3 to 7.1) 5

Common Device-Related Adverse Events:

• Asymptomatic bacteriuria: 23.4% 2
• Discomfort: 9.4% 2
• Urinary urgency: 7.5% 2
• No device-related serious adverse events reported 2

Historical Stent Complications (Context):

The AUA guidelines warn about prostatic stent complications including encrustation, occlusive regrowth, perineal pain, and discomfort on urination 4. However, the Spanner's temporary design with regular replacement mitigates these long-term complications.

Critical Clinical Pitfalls

1. Biggest mistake: Placing stent in patients unfit for surgery without confirming bladder contractility—this leads to 63% failure 3

2. Ignoring detrusor function: Success depends entirely on preserved bladder contractility; pressure-flow studies should be performed in questionable cases 6

3. Using as routine BPH treatment: The 2003 AUA guideline explicitly states stents should be considered "only in high-risk patients, especially those with urinary retention" due to significant complications 4

4. Exceeding recommended duration: Post-TUMT use should not exceed 4 weeks; extended use requires monthly replacement 1, 2

5. Inadequate follow-up: Weekly assessments in first month are essential to detect early complications

Guideline Context

The 2023 AUA Guideline Amendment added temporary implanted prostatic devices (TIPD) as a new category 7, recognizing the Spanner as the only FDA-approved temporary stent currently available in the United States 4. However, the fundamental principle remains: prostatic stents are reserved for high-risk patients with retention, not for routine symptomatic BPH management 4.

The 2021 AUA guidelines emphasize that most BPH patients should receive medical management (alpha-blockers, 5-alpha reductase inhibitors) or definitive surgical therapy (TURP, laser enucleation) 8. Stents occupy a narrow niche for patients who cannot tolerate these standard approaches but maintain bladder function.